PARIS--(BUSINESS WIRE)--The WIN Consortium is proud to announce the British Journal of Cancer (BJC), published by Nature Publishing Group, as the official media partner of the 3^rd WIN Symposium. BJC will be covering the symposium, which this year is dedicated to the challenging topic of addressing the efficacy of cancer therapeutics and the utility of diagnostics in the era of personalized medicine, in a the form of a supplement to be published later this year.

The event which is endorsed by ASCO, EORTC, ESMO, INCA and OECI will take place on 6-8 July 2011 in Paris.

This is your last chance to register for this unique event supported by Bristol Myers Squibb, Roche, AstraZeneca and Nerviano Medical Science, and meet worldwide oncology leaders from academia, pharma and biotech industries, as well as patient organizations.

As an example of the interactions between worldwide experts, an open forum will be organized, where a panel of experts will debate with attendees on challenging issues such as addressing the complexity of molecular pathways in cancer to inform the best therapeutic approaches and developing the most relevant combinations beyond individual Pharma/Biotech Pipelines by taking a risk sharing approach for the benefit of the patient.

Garry Gilliland (MERCK & Co), Nick Botwood, (AstraZeneca), Mike Burgess (ROCHE), John Mendelsohn, Chairman of the WIN Consortium, Richard L.Schilsky, Chairman of WIN SAB, and Alexander Eggermont, Director of the InstitutGustaveRoussy and many other leaders in this field will debate with the audience. Pr. Richard L. Schilsky will deliver the synthesis of the symposium and will present concrete perspectives to improve clinical outcomes and the quality of life for cancer patients worldwide.

The WIN Consortium www.winconsortium.org is a joint initiative from the Institut Gustave Roussy (France) and the University of Texas - MD Anderson Cancer Center (USA) which brings together 17 cancer centers around the world, the National Breast Cancer Foundation, Sage Bionetworks and three technology partners: Agilent Technologies, GE Healthcare and Life Technologies The mission of WIN is to conduct worldwide innovative clinical trials in order to accelerate the pace and to reduce the cost of translating effective cancer treatments to the patient.

Click here to read the detailed scientific program and to register for the WIN Symposium: http://www.winconsortium.org/symposium.html.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6780145&lang=en

Contacts